The pilot study launches in Q1-2021 and targets 88 PTSD veterans at two different VA hospitals. Although the placebo-controlled study is currently slated to finish in 2023, I added a year and guesstimated 1H-2024 for results.
That's a long time from today, but there's an interesting note. The study is using CORT108297.
We are seeing mifepristone (Korlym) being discarded across programs and replaced with newer and hopefully better drugs. CORT108297 has been used in animal models of AIWG, CNS disease, ECT treatment, and stress
. A long time ago, it was successfully deployed in a Phase 2 pilot of AIWG.